Loading...
XNAS
SRPT
Market cap2.15bUSD
Jul 09, Last price  
20.52USD
1D
1.53%
1Q
-3.12%
Jan 2017
-25.19%
Name

Sarepta Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:SRPT chart
P/E
—
P/S
0.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.10%
Rev. gr., 5y
32.41%
Revenues
2.20b
+15.58%
115,29110,985,19121,258,15517,585,00029,420,00046,990,00037,329,00014,219,0009,757,0001,253,0005,421,000154,584,000301,034,000380,833,000540,099,000701,887,000933,013,0001,243,336,0001,901,979,0002,198,237,000
Net income
-713m
L
-31,073,012-27,167,725-23,952,625-25,159,000-32,177,000-2,318,000-121,287,000-111,985,000-135,789,000-220,030,000-267,265,000-50,688,000-361,918,000-715,075,000-554,128,000-418,780,000-703,488,000-535,977,000235,239,000-713,410,000
CFO
-205m
L-0.15%
-20,613,369-24,677,155-12,339,313-8,800,000-15,209,000-23,679,000-29,694,000-64,695,000-128,539,000-149,465,000-245,820,000-231,996,000-388,660,000-456,463,000107,466,000-443,172,000-325,346,000-500,993,000-205,787,000-205,479,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
URL
https://www.sarepta.com/
IPO date
Jun 04, 1997
Employees
1,162
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT